The Latest

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

What's the Effect of Genvoya, the Newest Single-Tablet Regimen, on Older Adults Living With HIV?

In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.

By Olivia G. Ford

Tenofovir Alafenamide (TAF) in People With Kidney Dysfunction

In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety

A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.

By Warren Tong